Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Head & Neck 1

Conditions

Pain, Postoperative 1Pain 1Multiple Myeloma 1Mucositis 1Lymphoma 1Head and Neck Neoplasms 1Abnormalities, Radiation-Induced 1

Interventions

Radiotherapy 2Glutamine 2Fibroblast Growth Factor 7 2oxycodone-acetaminophen 1cyclohexaneacetic acid 1acetaminophen, hydrocodone drug combination 1Surveys and Questionnaires 1Sucralfate 1Standard of Care 1Passive Cutaneous Anaphylaxis 1Pain Management 1Neck Dissection 1Morphine 1Methods 1Methadone 1Laser Therapy 1Ketamine 1Ibuprofen 1Hydromorphone 1Gabapentin 1Fentanyl 1Educational Status 1Early Intervention, Educational 1Doxepin 1Cisplatin 1Benzydamine 1Analgesia 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Mucositis × oxycodone-acetaminophen × Clear all
NCT02480114 2021-02-18

Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy

Vanderbilt-Ingram Cancer Center

Phase 3 Completed
79 enrolled 8 charts
Head & NeckOther

Abnormalities, Radiation-Induced, Head and Neck Neoplasms, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡